-
2024-510714-32-00
4
2020-12-10
Patiens with locally advanced/metastatic endometrial carcinoma or cerv
-
2024-514104-14-00
4
2020-11-04
Adults subjects with advanced malignant pleural (cohort A) or peritone
-
2022-502052-30-00
5
2020-10-27
Unresectable Esophageal Squamous Cell Carcinoma
-
2023-510390-33-00
5
2020-10-23
HER2-negative breast cancer patients with high relapse risk after
stan
-
2023-504805-35-00
9
2020-10-22
Lymphoma of B-cell origin
-
2023-506365-64-00
5
2020-10-16
Deleterious Germline or Somatic Homologous Recombination Repair (HRR)
-
2023-505812-39-00
5
2020-08-28
HR+/HER2-Negative Locally Advanced or Metastatic Breast cancer with PI
-
2023-506588-32-00
5
2020-06-12
Relapsed and Lenalidomide-Refractory Multiple Myeloma
-
2023-506782-56-00
5
2020-03-10
RET-Mutant Medullary Thyroid Cancer
-
2023-508292-37-00
5
2020-03-06
Cardiovascular Disease
-
2024-518069-89-00
4
2020-02-03
Patients with solid cancers
-
2023-506587-13-00
4
2020-01-30
Multiple Myeloma
-
2024-512525-83-00
5
2020-01-07
Hypertension
-
2023-509049-11-00
5
2020-01-01
FIGO stage III ovarian cancer who are eligible for primary cytoreducti
-
2024-514829-36-00
5
2019-12-02
High-risk biochemically-relapsed prostate adenocarcinoma following rad
-
2022-502354-14-00
5
2019-10-28
Completely resected Stage IIb/c melanoma
-
2024-516847-23-00
4
2019-08-27
ER-positive and HER2-negative metastatic or locally advanced breast ca
-
2022-502616-37-00
9
2019-07-30
Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma (r/r B-cell NHL)
-
2024-515946-17-00
5
2019-07-22
Non Small Cell Lung Cancer
-
2024-514705-62-00
5
2019-07-08
Recurrent rectal cancer after local excision
-
2023-505223-31-00
4
2019-06-14
Localized ER+ breast cancer
-
2024-512165-13-00
4
2019-05-13
Localised unresectable adenocarcinoma or squamous cell carcinoma of th
-
2024-514706-31-01
5
2019-05-02
Epithelial ovarian cancer, Fallopian tube ovarian cancer, Peritoneal o
-
2023-506921-12-00
5
2018-12-27
ER+/HER2- Breast Cancer